S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
BREAKING: Tiny biotech successfully treats blindness (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Sprinklr Gets Targets Raised By Analysts, Here's Why
Time To Buy Uranium? Cameco Is The Top Pick
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
BREAKING: Tiny biotech successfully treats blindness (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Sprinklr Gets Targets Raised By Analysts, Here's Why
Time To Buy Uranium? Cameco Is The Top Pick
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
BREAKING: Tiny biotech successfully treats blindness (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Sprinklr Gets Targets Raised By Analysts, Here's Why
Time To Buy Uranium? Cameco Is The Top Pick
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
BREAKING: Tiny biotech successfully treats blindness (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Sprinklr Gets Targets Raised By Analysts, Here's Why
Time To Buy Uranium? Cameco Is The Top Pick
NASDAQ:CRTX

Cortexyme (CRTX) Stock Forecast, Price & News

$1.49
-0.03 (-1.97%)
(As of 06/7/2023 ET)
Compare
Today's Range
$1.35
▼
$1.56
50-Day Range
$1.43
▼
$1.79
52-Week Range
$1.78
▼
$40.66
Volume
189,445 shs
Average Volume
620,672 shs
Market Capitalization
$44.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media

CRTX stock logo

About Cortexyme (NASDAQ:CRTX) Stock

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Receive CRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cortexyme and its competitors with MarketBeat's FREE daily newsletter.

CRTX Stock News Headlines

June 4, 2023 | americanbankingnews.com
Cortexyme (NASDAQ:CRTX) Shares Pass Above 200-Day Moving Average of $1.08
May 5, 2023 | americanbankingnews.com
Analyzing Genenta Science (NASDAQ:GNTA) & Cortexyme (NASDAQ:CRTX)
June 8, 2023 | Behind the Markets (Ad)
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
August 1, 2022 | marketscreener.com
Cortexyme : Quince Therapeutics Details Strategic Growth Plan with Launch of New Corporate Name - Form 8-K - Marketscreener.com
July 27, 2022 | marketscreener.com
Cortexyme Completes Phase 1 Single, Multiple Ascending Dose Trial of Potential Alzheimer's Disease Treatment - Marketscreener.com
July 27, 2022 | businesswire.com
Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Business Wire
July 27, 2022 | businesswire.com
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Business Wire
July 27, 2022 | marketscreener.com
Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Marketscreener.com
June 8, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
July 27, 2022 | finance.yahoo.com
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Yahoo Finance
July 27, 2022 | finance.yahoo.com
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588
July 27, 2022 | finance.yahoo.com
Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022
July 22, 2022 | streetinsider.com
Cortexyme (CRTX) Announces Resignation of EVP of Research and Development - StreetInsider.com
June 26, 2022 | gurufocus.com
Bragar Eagel & Squire, PC Is Investigating Agrify, CareDx, Medallion, and Cortexyme and Encourages Investors to Contact the Firm - GuruFocus.com
June 21, 2022 | benzinga.com
Cortexyme Announces Preclinical Data Demonstrating Efficacy Of Cor803 For The Treatment Of Coronavirus In - Benzinga
June 21, 2022 | nasdaq.com
Cortexyme : Preclinical Data Show Efficacy Of COR803 For Coronavirus Infections Treatment - Nasdaq
June 21, 2022 | finance.yahoo.com
Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections
June 13, 2022 | businesswire.com
Cortexyme Appoints June Bray to its Board of Directors - Business Wire
June 13, 2022 | finance.yahoo.com
Cortexyme Appoints June Bray to its Board of Directors - Yahoo Finance
June 13, 2022 | finance.yahoo.com
Cortexyme Appoints June Bray to its Board of Directors
June 11, 2022 | marketscreener.com
Cortexyme, Inc. Announces Resignation of Christopher Lowe as Chief Financial Officer - Marketscreener.com
June 10, 2022 | marketscreener.com
Cortexyme : Statement of Changes in Beneficial Ownership (Form 4) - Marketscreener.com
May 22, 2022 | businesswire.com
Cortexyme Successfully Completes Acquisition of Novosteo - Business Wire
May 20, 2022 | nasdaq.com
This Is the Worst Type of Credit Card for Most Consumers - Nasdaq
May 20, 2022 | finance.yahoo.com
PPG Showcases Innovations in Paints, Coatings, Specialty Materials That Enhance Sustainability, Efficiency, Mobility - Yahoo Finance
May 20, 2022 | marketscreener.com
Cortexyme : Completion of Acquisition or Disposition of Assets - Form 8-K - Marketscreener.com
May 20, 2022 | finance.yahoo.com
Cortexyme Successfully Completes Acquisition of Novosteo - Yahoo Finance
See More Headlines

CRTX Price History

CRTX Company Calendar

Last Earnings
8/09/2021
Today
6/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological Products, Except Diagnostic
Sub-Industry
Health Care Technology
Sector
Medical
Current Symbol
NASDAQ:CRTX
CUSIP
21924P10
CIK
1145404
Web
www.cortexyme.com
Phone
(650) 910-5717
Fax
N/A
Employees
55
Year Founded
2012

Profitability

EPS (Most Recent Fiscal Year)
($2.97)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-89,940,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-70.96%
Return on Assets
-63.53%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.92
Quick Ratio
9.92

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.97 per share
Price / Book
0.38

Miscellaneous

Outstanding Shares
30,151,000
Free Float
21,739,000
Market Cap
$44.92 million
Optionable
Not Optionable
Beta
1.40

Social Links


Key Executives

  • Dr. Leslie J. Holsinger Ph.D. (Age 57)
    Exec. VP of R&D
    Comp: $603.85k
  • Dr. Dirk Thye M.D. (Age 52)
    CEO & Director
  • Mr. Ted Monohon (Age 56)
    VP of Fin., Principal Financial Officer & Chief Accounting Officer
  • Mr. Brendan Hannah M.B.A.
    Chief Bus. Officer
  • Dr. Karen L. Smith L.L.M (Age 54)
    L.L.M., M.B.A., M.D., PH.D., Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













CRTX Stock - Frequently Asked Questions

How have CRTX shares performed in 2023?

Cortexyme's stock was trading at $0.6374 at the beginning of 2023. Since then, CRTX shares have increased by 133.8% and is now trading at $1.49.
View the best growth stocks for 2023 here.

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) posted its earnings results on Monday, August, 9th. The biopharmaceutical company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.05.

What other stocks do shareholders of Cortexyme own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), DHT (DHT), EnLink Midstream (ENLC), Golar LNG Partners (GMLP), Matinas BioPharma (MTNB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI) and Tilly's (TLYS).

When did Cortexyme IPO?

(CRTX) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is Cortexyme's stock symbol?

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

Who are Cortexyme's major shareholders?

Cortexyme's stock is owned by a variety of institutional and retail investors. Top institutional investors include Simplex Trading LLC (0.00%). Insiders that own company stock include Caryn Gordon Mcdowell, Casey Lynch, Christopher P Lowe, David Lamond, Epiq Capital Group, Llc, Leslie Holsinger, Margaret Mcloughlin, Michael J Detke and Stephen S Dominy.
View institutional ownership trends.

How do I buy shares of Cortexyme?

Shares of CRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cortexyme's stock price today?

One share of CRTX stock can currently be purchased for approximately $1.49.

How much money does Cortexyme make?

Cortexyme (NASDAQ:CRTX) has a market capitalization of $44.92 million. The biopharmaceutical company earns $-89,940,000.00 in net income (profit) each year or ($2.97) on an earnings per share basis.

How can I contact Cortexyme?

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.cortexyme.com. The biopharmaceutical company can be reached via phone at (650) 910-5717 or via email at ir@cortexyme.com.

This page (NASDAQ:CRTX) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -